Have you ever failed to complete a course of antibiotics or missed the occasional dose of a cancer drug thinking it won’t kill you?
An interesting presentation by David Marin of the Hammersmith Hospital at the recent European Hematology Association (EHA) Congress in London highlighted how missing two or three doses per month of tyrosine kinase inhibitors for Chronic Myeloid Leukemia (CML) may have a dramatic effect on outcome.
Pieter Droppert on Biotech Strategy Blog has written more about the patient advocacy session at EHA 2011 where Dr Marin presented on CML adherence.
As Sally Church discusses on her EHA video blog, better patient and physician education is needed about adherence along with packaging of drugs that encourages compliance.
The take home is that even if you feel better, continuing to take a treatment may the right course of action in the long-term.
If you are interested in more information about CML adherence, then Jan Geissler, who chaired the EHA patient advocacy session, has posted more information on the CML Advocates Network website.